ArticleGastro hep advances2025
Comparative Analysis of Imaging Modalities for Surveillance on Outcomes in Patients With Hepatocellular Carcinoma.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The American Association for the Study of Liver Diseases recommends regular surveillance with ultrasonography (US) and alpha-feto protein every 6 months for patients at high risk of hepatocellular carcinoma (HCC). However, US is considered to be less effective than cross-sectional imaging modalities like computed tomography and magnetic resonance imaging for detecting early HCC. Limited data exist on the overall survival and receipt of curative treatment for patients undergoing surveillance with different imaging modalities. Methods: We retrospectively reviewed patients (n = 1954) diagnosed with HCC between January 2011 and June 2021. Patients who developed HCC while on strict semiannual surveillance were included in the study. We estimated survival using the Kaplan-Meier method and compared the outcomes on different modalities of imaging using the Log Rank test. We used univariate and multivariate Cox model to evaluate factors affecting survival. Results: A total of 183 patients developed HCC on semiannual surveillance with Imaging (115 with contrast-enhanced magnetic resonance imaging, 34 with multiphasic computed tomography and 34 with US) and alpha-feto protein. No significant difference was noted in overall survival or transplant-free survival based on the imaging modality employed for surveillance for at-risk patients. No correlation was found between the type of imaging modality for surveillance and receipt of curative treatment. Conclusion: Using surveillance program rigorously in at-risk patients, we did not find any association between the imaging modality and clinical outcomes in patients with HCC. It is likely that adherence to surveillance program irrespective of imaging modalities is more effective to influence the outcome, but it needs further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.